Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
UniQure NV, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
UniQure Acquires Patents from University of Padova 12
Venture Financing 13
uniQure Raises Additional USD10 Million in Venture Debt Financing 13
uniQure Raises US$10 Million In Venture Financing 14
UniQure Raises USD17.5 Million in Venture Financing 15
Partnerships 16
Bristol-Myers Squibb Enters into Agreement with uniQure 16
Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 17
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 18
Licensing Agreements 19
uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19
uniQure Enters into Licensing Agreement with Protein Sciences 20
uniQure Enters into Licensing Agreement with Cold Spring Harbor Laboratory 21
Treeway Enters into Licensing Agreement with uniQure 22
Benitec Biopharma Enters Into Licenising Agreement With uniQure 23
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 24
Equity Offering 25
uniQure Raises USD147.5 Million in Public Offering of Shares 25
uniQure Raises USD91.2 Million in Public Offering of Shares 27
uniQure Raises USD38 Million in Private Placement of Shares 29
uniQure Raises USD88.5 Million in Public Offering of Shares 30
uniQure Completes IPO For US$91.8 Million 32
InoCard Spin Out from University of Heidelberg 34
uniQure Announces Private Placement Of Shares For US$7.8 Million 35
Acquisition 36
UniQure Acquires InoCard for USD5.7 Million 36
uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 37
UniQure NV – Key Competitors 39
UniQure NV – Key Employees 40
UniQure NV – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Nov 06, 2018: uniQure announces third quarter 2018 financial results and highlights company progress 42
Aug 08, 2018: uniQure announces second quarter 2018 financial results and highlights company progress 44
Apr 30, 2018: uniQure Reports First Quarter 2018 Financial Results 47
Mar 14, 2018: uniQure Announces 2017 Financial Results and Recent Company Progress 49
Nov 01, 2017: uniQure Announces Third Quarter 2017 Financial Results and Recent Company Progress 51
Aug 08, 2017: uniQure Announces Second Quarter 2017 Financial Results and Recent Company Progress 54
May 09, 2017: uniQure Announces First Quarter 2017 Financial Results and Highlights Recent Company Progress 56
Mar 15, 2017: uniQure Announces 2016 Financial Results and Provides Update on Company Progress 58
Jan 25, 2017: uniQure Appoints Alexander Kuta as Senior Vice President of Regulatory Affairs 60
Corporate Communications 61
Jun 13, 2018: uniQure Announces New Appointments to its Board of Directors 61
Dec 11, 2017: uniQure Added to NASDAQ Biotechnology Index 62
Aug 07, 2017: uniQure Announces Leadership Team Appointments and Nominations to its Board of Directors 63
Jun 06, 2017: uniQure Announces Appointment of Steven L. Zelenkofske as Chief Medical Officer 65
Product News 66
12/09/2017: uniQure Announces Presentation of Non-Clinical Data of AMT-061 at the 59th American Society of Hematology (ASH) Annual Meeting 66
11/01/2017: uniQure Announces Presentations at the 59th American Society of Hematology Annual Meeting 67
07/21/2017: uniQure Announces the Successful Development and Scale-up of Manufacturing Processes for Its Hemophilia B Gene Therapy Program 69
07/11/2017: uniQure Presents New Clinical Data in Hemophilia B Patients Demonstrating Therapeutic Efficacy of AAV5 Gene Therapy in the Presence of Pre-Existing Neutralizing Antibodies 70
07/10/2017: uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B 71
06/23/2017: uniQure Announces Clinical Data Presentations at the Upcoming International Society on Thrombosis and Hemostasis Congress 73
Jun 15, 2017: uniQure Publishes Data Further Demonstrating Favorable Immunogenicity Profile and Broad Utilization of AAV5-Based Gene Therapies 74
May 11, 2017: uniQure Announces Successful Readministration of Gene Therapy in Non-Human Primates 75
04/24/2017: uniQure Announces Presentations at the Upcoming Annual Meeting of The American Society of Gene and Cell Therapy 76
04/04/2017: uniQure Publishes Data Demonstrating Wide Distribution of AAV5 in the Central Nervous System 77
02/06/2017: uniQure Announces Presentations at Upcoming February Conferences 78
Product Approvals 79
Apr 25, 2017: uniQure Receives European Medicines Agency Priority Medicines Designation for AMT-060 in Hemophilia B 79
Jan 30, 2017: uniQure Announces FDA Breakthrough Therapy Designation for AMT-060 in Hemophilia B 80
Clinical Trials 81
Oct 19, 2017: uniQure Announces Hemophilia B Gene Therapy Program To Enter Pivotal Study With FIX-Padua Variant in 2018 81
May 10, 2017: uniQure Presents New Data Demonstrating Successful and Effective Transduction of AAV5 Vector in the Presence of Pre-Existing Neutralizing Antibodies in Non-Human Primates 83
Apr 26, 2017: uniQure Presents New Preclinical Data on AMT-130 in Huntington’s Disease at CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference 84
Other Significant Developments 85
Jan 08, 2018: uniQure Provides Year-End 2017 Corporate Update and Outlines Near-Term Objectives to Further Drive Shareholder Value 85
Jan 09, 2017: uniQure Outlines Key Initiatives for 2017 and Vision for 2018 87
Appendix 88
Methodology 88
About GlobalData 88
Contact Us 88
Disclaimer 88
UniQure NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
UniQure NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
UniQure NV, Deals By Therapy Area, 2012 to YTD 2018 9
UniQure NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
UniQure Acquires Patents from University of Padova 12
uniQure Raises Additional USD10 Million in Venture Debt Financing 13
uniQure Raises US$10 Million In Venture Financing 14
UniQure Raises USD17.5 Million in Venture Financing 15
Bristol-Myers Squibb Enters into Agreement with uniQure 16
Synpromics Extends Co-Development Agreement with uniQure for Gene Therapy Vector 17
uniQure Enters Into Agreement With University of California, San Francisco To Develop Gene Therapy For Parkinson Disease 18
uniQure Enters into Licensing Agreement with 4D Molecular Therapeutics 19
uniQure Enters into Licensing Agreement with Protein Sciences 20
uniQure Enters into Licensing Agreement with Cold Spring Harbor Laboratory 21
Treeway Enters into Licensing Agreement with uniQure 22
Benitec Biopharma Enters Into Licenising Agreement With uniQure 23
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology 24
uniQure Raises USD147.5 Million in Public Offering of Shares 25
uniQure Raises USD91.2 Million in Public Offering of Shares 27
uniQure Raises USD38 Million in Private Placement of Shares 29
uniQure Raises USD88.5 Million in Public Offering of Shares 30
uniQure Completes IPO For US$91.8 Million 32
InoCard Spin Out from University of Heidelberg 34
uniQure Announces Private Placement Of Shares For US$7.8 Million 35
UniQure Acquires InoCard for USD5.7 Million 36
uniQure Acquires Amsterdam Molecular Therapeutics, Developer Of Gene Therapy 37
UniQure NV, Key Competitors 39
UniQure NV, Key Employees 40
UniQure NV, Subsidiaries 41
List of Figures
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
UniQure NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
UniQure NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
UniQure NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
UniQure NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9